[go: up one dir, main page]

WO2001049249A3 - Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix - Google Patents

Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Info

Publication number
WO2001049249A3
WO2001049249A3 PCT/US2001/000030 US0100030W WO0149249A3 WO 2001049249 A3 WO2001049249 A3 WO 2001049249A3 US 0100030 W US0100030 W US 0100030W WO 0149249 A3 WO0149249 A3 WO 0149249A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
regulating
active compounds
polymer matrix
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/000030
Other languages
French (fr)
Other versions
WO2001049249A2 (en
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Priority to AU29255/01A priority Critical patent/AU784226B2/en
Priority to CA002396037A priority patent/CA2396037A1/en
Priority to JP2001549618A priority patent/JP2003519164A/en
Priority to US10/169,410 priority patent/US7521061B2/en
Priority to EP01939971A priority patent/EP1263453A4/en
Publication of WO2001049249A2 publication Critical patent/WO2001049249A2/en
Publication of WO2001049249A3 publication Critical patent/WO2001049249A3/en
Anticipated expiration legal-status Critical
Priority to US12/426,902 priority patent/US20090285895A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A formulation containing a biologically active compound having a structure with hydrogen bonding sites is blended with a polymer having a structure with complementary hydrogen bonding sites, the polymer forming hydrolytic degradation products that promote the release of the biologically active compound from the polymer.
PCT/US2001/000030 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix Ceased WO2001049249A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU29255/01A AU784226B2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
CA002396037A CA2396037A1 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
JP2001549618A JP2003519164A (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for controlled release of bioactive compounds based on polymer matrix
US10/169,410 US7521061B2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
EP01939971A EP1263453A4 (en) 1999-12-31 2001-01-02 PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES
US12/426,902 US20090285895A1 (en) 1999-12-31 2009-04-20 Pharmaceutical Formulation for Regulating the Timed Release of Biologically Active Compounds Based on a Polymer Matrix

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US60/174,137 1999-12-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/426,902 Continuation US20090285895A1 (en) 1999-12-31 2009-04-20 Pharmaceutical Formulation for Regulating the Timed Release of Biologically Active Compounds Based on a Polymer Matrix

Publications (2)

Publication Number Publication Date
WO2001049249A2 WO2001049249A2 (en) 2001-07-12
WO2001049249A3 true WO2001049249A3 (en) 2002-01-17

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000030 Ceased WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Country Status (5)

Country Link
EP (1) EP1263453A4 (en)
JP (1) JP2003519164A (en)
AU (1) AU784226B2 (en)
CA (1) CA2396037A1 (en)
WO (1) WO2001049249A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8592450B2 (en) 2005-05-17 2013-11-26 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049311A1 (en) 1999-12-31 2001-07-12 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1682537E (en) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Modulators of cellular adhesion
MX2008010126A (en) 2006-02-08 2010-02-22 Tyrx Pharma Inc Temporarily stiffened mesh prostheses.
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
AU2007351374B2 (en) 2006-11-06 2012-11-08 Medtronic, Inc. Mesh pouches for implantable medical devices
EP2129339B1 (en) 2007-03-29 2015-03-04 Tyrx, Inc. Biodegradable, polymer coverings for breast implants
AU2008247455B2 (en) 2007-05-02 2013-12-05 Medtronic, Inc. Dihydroxybenzoate polymers and uses thereof
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010006046A1 (en) 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Nsaid delivery from polyarylates
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010033995A1 (en) 2008-09-22 2010-03-25 Tyrx Pharma, Inc. Linear polyesteramides from aminophenolic esters
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
JP5847706B2 (en) * 2009-06-01 2016-01-27 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． Compositions and methods for preventing sternum wound infections
WO2011014858A1 (en) * 2009-07-31 2011-02-03 Rutgers, The State University Of New Jersey Bioresorbable polymers synthesized from monomer analogs of natural metabolites
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
AU2011293344B2 (en) 2010-08-25 2015-07-30 Medtronic, Inc. Novel medical device coatings
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2816343C (en) 2010-11-12 2017-01-17 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
EP2734248B1 (en) 2011-07-20 2018-10-17 Tyrx, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
HK1220611A1 (en) 2013-03-15 2017-05-12 Bausch Health Ireland Limited Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
CN105431178A (en) 2013-11-08 2016-03-23 泰尔克斯公司 Antimicrobial compositions and methods for preventing surgical incision site infection
WO2016020308A1 (en) * 2014-08-04 2016-02-11 Janssen Sciences Ireland Uc Compacted solid dosage form
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670602A (en) * 1995-03-31 1997-09-23 Rutgers, The State University Synthesis of tyrosine-derived diphenol monomers
US5962471A (en) * 1997-05-13 1999-10-05 Hoechst Aktiengesellschaft Substituted 6- and 7-aminotetrahydroisoquinolinecarboxylic acids
WO2000046854A1 (en) * 1999-02-05 2000-08-10 Alien Technology Corporation Apparatuses and methods for forming assemblies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
CA2281614C (en) * 1997-02-18 2008-11-18 Rutgers, The State University Of New Jersey Monomers derived from hydroxy acids and polymers prepared therefrom
AR014940A1 (en) * 1997-12-12 2001-04-11 Expression Genetics Inc A CARRIER FOR THE RELEASE OF A BIOACTIVE AGENT, A BIODEGRADABLE POLYESTER POLYMER, COPOLIMEROS AND PHARMACEUTICAL COMPOSITIONS THAT CONNECT THEM.
JP4312384B2 (en) * 1998-04-13 2009-08-12 ラットガーズ ザ ステイト ユニヴァーシティ Construction of copolymer library

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670602A (en) * 1995-03-31 1997-09-23 Rutgers, The State University Synthesis of tyrosine-derived diphenol monomers
US5962471A (en) * 1997-05-13 1999-10-05 Hoechst Aktiengesellschaft Substituted 6- and 7-aminotetrahydroisoquinolinecarboxylic acids
WO2000046854A1 (en) * 1999-02-05 2000-08-10 Alien Technology Corporation Apparatuses and methods for forming assemblies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1263453A4 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045457B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US9045458B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US10188641B2 (en) 2005-05-17 2019-01-29 Sarcode Bioscience Inc. Compositions and methods for treatment
US8592450B2 (en) 2005-05-17 2013-11-26 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8758776B2 (en) 2005-05-17 2014-06-24 Sarcode Bioscience Inc. Compositions and methods for treatment
US8771715B2 (en) 2005-05-17 2014-07-08 Sarcode Bioscience Inc. Compositions and methods for treatment
US9051297B2 (en) 2005-05-17 2015-06-09 Sarcode Bioscience Inc. Compositions and methods for treatment
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US8367701B2 (en) 2008-04-15 2013-02-05 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8871935B2 (en) 2008-04-15 2014-10-28 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US11028077B2 (en) 2008-04-15 2021-06-08 Novartis Pharmaceuticals Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8927574B2 (en) 2009-10-21 2015-01-06 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10214517B2 (en) 2012-07-25 2019-02-26 Sarcode Bioscience Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10906892B2 (en) 2012-07-25 2021-02-02 Novartis Pharmaceuticals Corporation LFA-1 inhibitor and methods of preparation and polymorph thereof

Also Published As

Publication number Publication date
AU2925501A (en) 2001-07-16
JP2003519164A (en) 2003-06-17
WO2001049249A2 (en) 2001-07-12
EP1263453A4 (en) 2008-02-20
EP1263453A2 (en) 2002-12-11
CA2396037A1 (en) 2001-07-12
AU784226B2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2001049249A3 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
WO1999036099A8 (en) Sustained release compositions, process for producing the same and utilization thereof
AU3904099A (en) Drug delivery module
EP1464673A3 (en) Polyanhydrides with biologically active degradation products
EP1193270A3 (en) Pyrrolobenzodiazepines
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
AU5945396A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
AU7547196A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU6701198A (en) Timed-release localised drug delivery by percutaneous administration
WO2000007979A3 (en) Compounds and compositions for delivering active agents
EP1093819A3 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
AU4194799A (en) Multimolecular devices, drug delivery systems and single-molecule selection
WO2001035941A8 (en) Novel composition based on a thiazolidinedione and metformin and use
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
AU7962200A (en) Novel indole derivatives and drugs containing the same as the active ingredient
AU1095801A (en) Antimicrobial compositions comprising a biologically active organic acid
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
AU1689999A (en) Medicinal composition for percutaneous administration
AU2084801A (en) Antiviral medication
AU6440600A (en) Combination of active agents, said combination containing clonidine
AU5812800A (en) Pharmaceutical preparation
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
AU5290199A (en) Erythromycin derivatives with antibiotic activity
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2396037

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 549618

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 29255/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001939971

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10169410

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001939971

Country of ref document: EP